Neuroendocrine Tumor Clinical Trials
Here are the 6 most popular medical studies for neuroendocrine tumor
Tyrosine Kinase Inhibitor
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate for Neuroendocrine Tumors
This trial is researching a newly described class of tumors that can occur de novo or over time, and will use special imaging to measure their impact on the body.
Neuroendocrine Tumors Clinical Trials
View 59 Neuroendocrine Tumors medical studies.
DSNET Clinical Trials
View 59 DSNET medical studies.
Metastatic Neuroendocrine Tumor Clinical Trials
View 71 metastatic neuroendocrine tumor medical studies.
ADCT-701 for Cancer
This trial tests a new drug for adults with rare cancers in the digestive system, pancreas, lungs, and other parts of the body. Participants will have tests and receive the drug every 21 days for up to 2 years, with follow-up for up to 5 years.
CAR T-cell Therapy
TIL + Fludarabine + Cyclophosphamide for Advanced Solid Cancers
This trial is testing a new treatment for cancer that involves removing some lymph nodes, infusing the patient with their own tumor cells, and then giving them a high dose of aldesleukin. The goal is to see if this can help patients with locally advanced, recurrent, or metastatic cancer.
Phase 3 Neuroendocrine Tumor Clinical Trials
View 71 phase 3 neuroendocrine tumor medical studies.
68Ga-DOTA-TATE Imaging for Neuroendocrine Tumors
This trial is to establish the safety of a new PET radiotracer, 68Ga-DOTA-TATE, for diagnosing neuro-endocrine cancer patients. The trial is prospective, open-label, and single-center with recruitment across Canada. There is no control group.
Octreotide + Interferon or Bevacizumab for Neuroendocrine Tumor
This trial is comparing two treatments for neuroendocrine tumors - octreotide acetate with either recombinant interferon alfa-2b or bevacizumab. The goal is to see if octreotide acetate with recombinant interferon alfa-2b is more effective than with bevacizumab.
Neuroendocrine Tumor Clinical Trials With No Placebo
View 71 neuroendocrine tumor medical studies that do not have a placebo group.
View More Neuroendocrine Tumor Trials
See another 46 many medical studies focused on neuroendocrine tumor.
68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
Frequently Asked Questions
Introduction to neuroendocrine tumor
What are the top hospitals conducting neuroendocrine tumor research?
In the realm of neuroendocrine tumor research, several top hospitals across the United States are leading the charge. Situated in Chicago, Northwestern University boasts an impressive seven ongoing clinical trials focused on this rare condition, while also having conducted 14 pioneering studies since their first recorded trial in 2002. Meanwhile, Memorial Sloan Kettering Cancer Center in New Yorkg Cancer Center in New York has made significant strides with six active trials and a total of 20 completed trials since embarking on their first neuroendocrine tumor investigation in 2008.
Further south, Tampa's Moffitt Cancer Center is making its mark with five current neuroendocrine tumor trials and a commendable track record of 17 previous investigations dating back to their inaugural study in 2007. In Bethesda, the National Institutes of Health Clinical Center is at the forefront as well, currently conducting six active clinical trials for neuroendocrine tumors and documenting a history of 13 past studies since initiating research in this area in 2009.
Notably contributing to this field is Mayo Clinic located within Rochester where they are actively pursuing further knowledge through five concurrent clinical tests related to neuroendocrine tumors while previously achieving twelve important breakthroughs from starting point back until same year as Moffit did i.e.,in2007.
These esteemed institutions serve as beacons of hope within the medical community by relentlessly striving for advancements that benefit patients affected by neuroendocrine tumors. The dedication shown through these clinical trials represents progress towards better understanding this complex condition and ultimately improving patient outcomes nationwide
Which are the best cities for neuroendocrine tumor clinical trials?
When it comes to neuroendocrine tumor clinical trials, several cities emerge as top contenders for research and advancements. Los Angeles, California leads the way with 18 active trials focusing on treatments like Bevacizumab, Capecitabine, and temozolomide. Boston, Massachusetts, California leads the way with 18 active trials focusing on treatments like Bevacizumab, Capecitabine, and temozolomide. Boston, Massachusetts closely follows with 17 ongoing studies exploring LEE011, pralsetinib (BLU-667), Cabozantinib, among others. New York City also stands out with 15 active trials investigating Phase 1b trials and promising therapies such as pralsetinib (BLU-667) and RYZ101. In addition to these cities, Chicago in Illinois and Tampa in Florida contribute significantly to neuroendocrine tumor clinical research through their respective active trial programs. These cities collectively offer individuals diagnosed with neuroendocrine tumors access to cutting-edge treatment options through participation in innovative clinical trials that hold potential for improved outcomes and quality of life.
Which are the top treatments for neuroendocrine tumor being explored in clinical trials?
Neuroendocrine tumors have seen significant advancements in treatment options through clinical trials. Among the top contenders are pembrolizumab, a drug currently being explored in two active trials and has been part of nine all-time neuroendocrine tumore all-time neuroendocrine tumor trials since its introduction in 2015. Another promising treatment is cabozantinib, involved in two ongoing trials and seven all-time neuroendocrine tumor studies since 2012. In addition, capecitabine showcases potential with its involvement in two active trials and participation in nine all-time neuroendocrine tumor studies dating back to 2005. Lastly, lutetium Lu 177 dotatate emerges as a newcomer with promise, already engaged in two active clinical trials for neuroendocrine tumors following its listing just last year. These innovative treatments offer hope for patients battling this complex disease by expanding the arsenal against it.
What are the most recent clinical trials for neuroendocrine tumor?
Exciting advancements are being made in the field of neuroendocrine tumor treatment, with several recent clinical trials offering hope for patients. A Phase 4 trial has demonstrated promising results by combining surgical debulking and 177Lu dotatate therapy. Additionally, a Phase 1/Phase 2 trial focused on dose escalation shows potential for improving outcomes in neuroendocrine tumor patients. Another study explores the combination of lenvatinib and pembrolizumab as a treatment approach, displaying encouraging results thus far. Furthermore, peptide receptor radionuclide therapy combined with cytoreductive surgery is being investigated through a Phase 1/Phase 2 trial to determine its effectiveness against this type of tumor. Lastly, cabozantinib has shown promise as an alternative therapeutic option in a Phase 1 trial. These recent clinical trials provide optimism for enhanced treatment approaches in tackling neuroendocrine tumors moving forward.
What neuroendocrine tumor clinical trials were recently completed?
In the realm of neuroendocrine tumor research, several noteworthy clinical trials have recently concluded, showcasing progress in the field. Among these trials, Pembrolizumab underwent assessment under the sponsorship of Jonsson Comprehensive Cancer Center and was completed in December 2018. In January 2018, Xencor, Inc., successfully conducted a trial on XmAb18087. Additionally, Memorial Sloan Kettering Cancer Center's study on Octreotide wrapped up in September 2017 alongside Peter Anderson's trial for ONC201 which concluded in August that same year. Further back in time to February 2017 and with sponsorship from the National Cancer Institute (NCI), an investigation into Sapanisertib reached completion. Lastly, H. Lee Moffitt Cancer Center and Research Institute sponsored a Pasireotide Long Acting Release (LAR) trial that finished its course back in February 2011.